Vrselja, Zvonimir
Daniele, Stefano G.
Silbereis, John
Talpo, Francesca
Morozov, Yury M.
Sousa, André M. M.
Tanaka, Brian S.
Skarica, Mario
Pletikos, Mihovil
Kaur, Navjot
Zhuang, Zhen W.
Liu, Zhao
Alkawadri, Rafeed
Sinusas, Albert J.
Latham, Stephen R.
Waxman, Stephen G.
Sestan, Nenad
Article History
Received: 22 February 2018
Accepted: 1 March 2019
First Online: 17 April 2019
Competing interests
: Z.V., S.G.D., J.S. and N.S. have disclosed these findings to the Yale Office of Cooperative Research, which has filed a patent to ensure broad use of the technology. All protocols, methods, perfusate formulations, and components of the Brain<i>Ex</i> technology remain freely available for academic and non-profit research. While the Hemopure product was provided in accordance to a material transfer agreement between HbO<sub>2</sub> Therapeutics and Yale University via N.S., the Company had no influence on the study design or interpretation of the results. No author has a financial stake in, or receives compensation from, HbO<sub>2</sub> Therapeutics. All other authors declare no competing interests.